← Back to Clinical Trials
Recruiting NCT06943131

NCT06943131 YWTL Exercises and Close Kinetic Chain Exercises in Children With Scapular Dyskinesis.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06943131
Status Recruiting
Phase
Sponsor Riphah International University
Condition Scapular Dyskinesis
Study Type INTERVENTIONAL
Enrollment 22 participants
Start Date 2025-02-15
Primary Completion 2025-07-15

Eligibility & Interventions

Sex All sexes
Min Age 9 Years
Max Age 12 Years
Study Type INTERVENTIONAL
Interventions
YWTL EXERCISESClosed kinetic chain exercises

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 22 participants in total. It began in 2025-02-15 with a primary completion date of 2025-07-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Scapular dyskinesia is defined by abnormal movement or placement of the scapula, the shoulder blade, during arm movements. Physical treatment aimed at regaining appropriate scapular mechanics through strengthening exercises, postural correction, and functional movement training is typically part of management. A randomized clinical trial will be conducted. The study will be conducted at Unique school and on school going children in a total duration of 10 months. Sample size will be 22.There will be two study groups. A convenient sampling technique will be used. The sample which will have following characteristics will be included children with age group 9 to 12 years, positive scapular test, positive scapular assistance test, athletes who practice one hour three days a week. The sample with the following characteristics will be excluded. Any muscular or joint deformity, scoliosis, shoulder dislocation. The tools that will be included in the study are modified lateral scapular test, shoulder flexion test, shoulder and pain disability index, upper extremity functional use scale, posture and posture assessment scale, shoulder and scapular ranges.

Eligibility Criteria

Inclusion Criteria: Children with an age group of 9 to 12 years. * Both genders. * Engage in overhead sports. * Minimum play time is 1 hour 3 times in a week. * Positive Modified lateral scapular test * Positive scapular dyskinesis shoulder flexion test * Positive scapular assistance test * Shoulder and pain disabilty index (score 1 to 20 ) * Upper extremity functional use scale (score 60 to 80). Exclusion Criteria: Any muscular or joint deformity. * Scoliosis. * Shoulder dislocation * Post fracture. * Neurological deficits * Cervicobrachialgia

Contact & Investigator

Central Contact

Imran Amjad, PHD

✉ imran.amjad@riphah.edu.pk

📞 9233224390125

Principal Investigator

Mishal Farwa, MS-PT

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT06943131 clinical trial?

This trial is open to participants of all sexes, aged 9 Years or older, up to 12 Years, studying Scapular Dyskinesis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06943131 currently recruiting?

Yes, NCT06943131 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.

Where is the NCT06943131 trial being conducted?

This trial is being conducted at Lahore, Pakistan.

Who is sponsoring the NCT06943131 clinical trial?

NCT06943131 is sponsored by Riphah International University. The principal investigator is Mishal Farwa, MS-PT at Riphah International University. The trial plans to enroll 22 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology